Clinical Trials
40 trialsHigh Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
University of Arkansas
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
M.D. Anderson Cancer Center
REALIZE
University of Oklahoma
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
University of Miami
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
University of Utah
EASE
AHS Cancer Control Alberta
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
LIBERATE
University Health Network, Toronto
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
University of Maryland, Baltimore
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Monash University
HEME Home Transfusion Program
Dana-Farber Cancer Institute
Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Washington University School of Medicine
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
MYRACLE
Nantes University Hospital
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
BAH2573
Essen Biotech
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Second Affiliated Hospital, School of Medicine, Zhejiang University
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Longitudinal Data Registry of Plasma Cell Dyscrasia
Shanghai Zhongshan Hospital
Survivorship
University of Modena and Reggio Emilia
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
PRONTO
Insel Gruppe AG, University Hospital Bern
Myelofludate
Nantes University Hospital
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Peking Union Medical College Hospital
RATIONALISE
Monash University
Bergamo Lymphoid Cancer Registry
A.O. Ospedale Papa Giovanni XXIII
ENROL
Hospital Universitari Vall d'Hebron Research Institute
CAR-T
Xuzhou Medical University
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
TMF-Allo
University Hospital, Clermont-Ferrand